We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Halozyme Therapeutics Incorporated | NASDAQ:HALO | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.04 | 2.55% | 41.90 | 39.50 | 42.00 | 41.66 | 40.87 | 41.10 | 1,281,727 | 00:55:48 |
|
|
|
Delaware
|
|
88-0488686
|
(State or Other Jurisdiction of Incorporation or Organization)
|
|
(I.R.S. Employer Identification No.)
|
|
|
|
Large accelerated filer
þ
|
|
Accelerated filer
¨
|
|
Non-accelerated filer
o
|
|
Smaller reporting company
o
|
|
|
|
|
(Do not check if a smaller reporting company)
|
|
|
|
|
|
|
|
|
|
|
|
Title of Securities to be Registered
|
|
Amount to be Registered (1)
|
|
Proposed Maximum
Offering Price per Share (2) |
|
Proposed Maximum
Aggregate Offering Price |
|
Amount of Registration Fee
|
Common Stock $0.001 par value per share, to be issued pursuant to the Amended and Restated 2011 Stock Plan
|
|
6,500,000
|
|
$9.58
|
|
$62,270,000
|
|
$6,271
|
(1)
|
Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “
Securities Act
”), this registration statement includes such indeterminable number of additional shares as may be issued as a result of an adjustment to the shares by reason of a stock split, stock dividend or similar capital adjustment, as required by the Amended and Restated Halozyme Therapeutics, Inc. 2011 Stock Plan.
|
(2)
|
This estimate is computed in accordance with Rules 457(c) and 457(h) under the Securities Act solely for the purpose of calculating the registration fee, and is based on the average of the high and low prices of the Registrant’s common stock on May 6, 2016, as reported on the NASDAQ Global Select Market.
|
|
HALOZYME THERAPEUTICS, INC.
|
|
||
|
By:
|
/s/ Helen I. Torley, M.B. Ch.B., M.R.C.P.
|
|
|
|
|
Helen I. Torley, M.B. Ch.B., M.R.C.P.
|
|
|
|
|
President and Chief Executive Officer
|
|
Signature
|
|
Title(s)
|
|
Date
|
|
|
|
|
|
/s/ Helen I. Torley, M.B. Ch.B., M.R.C.P.
Helen I. Torley, M.B. Ch.B., M.R.C.P.
|
|
President, Chief Executive Officer, and Director (Principal Executive Officer)
|
|
May 9, 2016
|
|
|
|
|
|
/s/ Laurie Stelzer
Laurie Stelzer
|
|
Senior Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)
|
|
May 9, 2016
|
|
|
|
|
|
/s/ Connie L. Matsui
Connie L. Matsui
|
|
Chairman of the Board of Directors
|
|
May 9, 2016
|
|
|
|
|
|
/s/ Jean-Pierre Bizzari, M.D.
Jean-Pierre Bizzari, M.D.
|
|
Director
|
|
May 9, 2016
|
|
|
|
|
|
/s/ James M. Daly
James M. Daly
|
|
Director
|
|
May 9, 2016
|
|
|
|
|
|
/s/ Jeffrey W. Henderson
Jeffrey W. Henderson
|
|
Director
|
|
May 9, 2016
|
|
|
|
|
|
/s/ Kathryn E. Falberg
Kathryn E. Falberg
|
|
Director
|
|
May 9, 2016
|
|
|
|
|
|
/s/ Kenneth J. Kelley
Kenneth J. Kelley
|
|
Director
|
|
May 9, 2016
|
|
|
|
|
|
/
Randal J. Kirk
|
|
Director
|
|
|
|
|
|
|
|
/s/ Mathew L. Posard
Matthew L. Posard
|
|
Director
|
|
May 9, 2016
|
EXHIBIT INDEX
|
||
|
|
|
Exhibit No.
|
|
Description
|
4.1(1)
|
|
Composite Certificate of Incorporation
|
4.2(2)
|
|
Bylaws, as amended
|
5.1
|
|
Opinion of DLA Piper LLP (US)
|
23.1
|
|
Consent of DLA Piper LLP (US) (filed as part of Exhibit 5.1)
|
23.2
|
|
Consent of Independent Registered Public Accounting Firm
|
24.1
|
|
Power of Attorney (included on the signature page to this registration statement)
|
99.1(3)
|
|
Halozyme Therapeutics, Inc. Amended and Restated 2011 Stock Plan
|
|
|
|
(1)
|
|
Incorporated by reference to the Registrant’s Current Report on Form 8-K, filed August 7, 2013.
|
(2)
|
|
Incorporated by reference to the Registrant’s Current Report on Form 8-K, filed December 12, 2011.
|
(3)
|
|
Incorporated by reference to the Registrant’s Definitive Proxy Statement, filed March 23, 2016.
|
1 Year Halozyme Therapeutics Chart |
1 Month Halozyme Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions